EMA

The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.

www.ema.europa.eu

EMA RSS Channel

Display # 
Title Published Date
Launch of PRIME - Paving the way for promising medicines for patients 10 March 2016
Human medicines: highlights of 2015 22 January 2016
EMA's medical literature monitoring enters into full operation 09 September 2015
EMA and US FDA release first conclusions of parallel assessment of quality-by-design applications 21 August 2013
European Medicines Agency website on suspected side effect reports now in all 23 EU official languages 19 June 2012
European Medicines Agency boosts EU transparency 31 May 2012
European Medicines Agency and United States Food and Drug Administration to share manufacturing site inspections 11 December 2011
European Medicines Agency starts new review of cardiovascular risks of non-selective NSAIDs 24 October 2011
European Medicines Agency reviews further data on narcolepsy and possible association with Pandemrix 22 February 2011
European Medicines Agency completes its review of Avastin used in breast cancer 16 December 2010
European Medicines Agency and ENCePP launch electronic Register of Studies 25 November 2010
European Medicines Agency and U.S. Food and Drug Administration extend confidentiality arrangements 20 September 2010
European Medicines Agency holds international workshop on clinical trials 15 September 2010
European Medicines Agency starts review of Pandemrix 31 August 2010
EMA and US FDA seek potential candidate companies for joint GMP inspection programme 12 August 2010
European Medicines Agency starts review of rosiglitazone-containing medicines 15 July 2010
European Medicines Agency implements internal reorganisation 12 October 2009
The bacterial challenge - time to react 18 September 2009
European Medicines Agency review of pandemic vaccines underway 25 July 2009
European public health agencies evaluate antibiotic resistance of Staphylococcus aureus 17 June 2009

Most Popular Now

Brilinta preferred over clopidogrel…

AstraZeneca today confirmed that the American College of Cardiology (ACC) and American Heart Association (AHA) have released a treatment guideline on the duration of dual...

Read more

NIH launches large clinical trials …

Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the A...

Read more

Pandemic influenza vaccine receives…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europe...

Read more

Saxenda® demonstrated significant i…

Today, new data from the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at th...

Read more

AstraZeneca and Eli Lilly and Compa…

AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in...

Read more

World's first public dengue immuniz…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today that the first public dengue immunization program has started in the Philippines. At a major l...

Read more

Vitamin D improves heart function, …

A daily dose of vitamin D3 improves heart function in people with chronic heart failure, a five-year University of Leeds research project has found. Dr Klaus Witte, from ...

Read more

Pfizer announces termination of pro…

Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The deci...

Read more

New analysis shows only minority of…

Boehringer Ingelheim has announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not ...

Read more

New insights in cancer therapy from…

Researchers in the group of Prof. Dr. Peter Vandenabeele (VIB/UGent) show that killed tumour cells can serve as a potent vaccine that stimulates the immune system to prev...

Read more

Researchers open the way to new tre…

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length struc...

Read more

Physicians' knowledge about FDA app…

Since 2012, the FDA can designate a drug as a "breakthrough therapy" if preliminary clinical evidence - such as an improvement in a pharmacodynamic biomarker - suggests a...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]